Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Published Online: 2013-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Bernard Escudier•Brad Rosbrook•Brian I Rini•Connie Chen•Jamal Tarazi•M Dror Michaelson•Martin E Gore•Piotr Tomczak•Robert J Motzer•Sinil Kim•Stephane Oudard•Subramanian Hariharan•Sylvie Negrier•Thomas E Hutson
